Drugs activating SPRY2 or inhibiting the downstream FGFR2 signalling could also play similar effects on suppressing ICC progression, like inhibiting FGFR2 directly with FGFR2 inhibitor. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.